Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 4, pp. 473-479
Open Access | Times Cited: 167

Showing 1-25 of 167 citing articles:

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 829
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 407
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim Papp, Andrew Blauvelt, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 487-498
Closed Access | Times Cited: 215
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 206
Paradoxical gastrointestinal effects of interleukin-17 blockers
Marine Fauny, David Moulin, Ferdinando D’Amico, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 9, pp. 1132-1138
Open Access | Times Cited: 180
Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment
G. Fragoulis, Christina Liava, Dimitrios Daoussis, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 18, pp. 2162-2176
Open Access | Times Cited: 171
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
Esther von Stebut, Wolf‐­Henning Boehncke, Kamran Ghoreschi, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 163
IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis
Zhenzhen Deng, Shengfeng Wang, Cuifang Wu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 43
Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD
Irma Tindemans, Maria E. Joosse, Janneke N. Samsom
Cells (2020) Vol. 9, Iss. 1, pp. 110-110
Open Access | Times Cited: 120
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Désirée van der Heijde, Lianne S. Gensler, Atul Deodhar, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 5, pp. 595-604
Open Access | Times Cited: 114
Comorbidities associated with psoriatic arthritis: Review and update
Lourdes M. Pérez-Chada, Joseph F. Merola
Clinical Immunology (2020) Vol. 214, pp. 108397-108397
Closed Access | Times Cited: 108
IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa
Jean M. Fletcher, Barry Moran, Andreea Petrasca, et al.
Clinical & Experimental Immunology (2020) Vol. 201, Iss. 2, pp. 121-134
Open Access | Times Cited: 106
Secukinumab: A Review in Ankylosing Spondylitis
Hannah A. Blair
Drugs (2019) Vol. 79, Iss. 4, pp. 433-443
Open Access | Times Cited: 99
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges
Daniele Noviello, Riccardo Mager, Giulia Roda, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 86
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 84
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
Hélène Bugaut, S. Aractingi
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases
S.P. Déo-Gracias Berry, Camille Dossou, Ali Kashif, et al.
International Immunopharmacology (2021) Vol. 102, pp. 108402-108402
Closed Access | Times Cited: 70
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
Yamin Shu, Yufeng Ding, Yanxin Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 63
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 61
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00698-adv00698
Open Access | Times Cited: 55
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database
Vishnu Eshwar, Ashwin Kamath
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment
Immo Prinz, Inga Sandrock, Ulrich Mrowietz
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 1
Open Access | Times Cited: 74
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Pascale Zwicky, Susanne Unger, Burkhard Becher
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 1
Open Access | Times Cited: 69
Axial psoriatic arthritis: An update for dermatologists
Alice B. Gottlieb, Joseph F. Merola
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 92-101
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top